Sustained Improvement of Cystic Fibrosis Lung Disease following Initiation of Elexacaftor/Tezacaftor/Ivacaftor Therapy: Lessons from Real-World Studies-Reference-Cited by-同舟云学术

Sustained Improvement of Cystic Fibrosis Lung Disease following Initiation of Elexacaftor/Tezacaftor/Ivacaftor Therapy: Lessons from Real-World Studies

Published:2023-11-01 Issue:9 Volume:208 Page:911-913
ISSN:1073-449X
Container-title:American Journal of Respiratory and Critical Care Medicine
language:en
Short-container-title:Am J Respir Crit Care Med

Author:

Steinke Eva¹²³,Stahl Mirjam¹²³^ORCID

Affiliation:

1. Department of Pediatric Respiratory Medicine, Immunology and Critical CareMedicine and Cystic Fibrosis CenterCharité – Universitätsmedizin BerlinBerlin, Germany

2. Berlin Institute of Health at Charité – Universitätsmedizin BerlinBerlin, Germany

3. German Center for Lung Research (DZL)Associated Partner SiteBerlin, Germany

Publisher

American Thoracic Society

Subject

Critical Care and Intensive Care Medicine,Pulmonary and Respiratory Medicine

Link

https://www.atsjournals.org/doi/pdf/10.1164/rccm.202309-1646ED

Reference15 articles.

1. Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on CFTR Function in Patients with Cystic Fibrosis and One or Two F508del Alleles

2. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial

3. Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele

4. Triple Therapy for Cystic Fibrosis Phe508del–Gating and –Residual Function Genotypes

5. Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for F508del and a Minimal Function Mutation: A Phase 3b, Randomized, Placebo-controlled Study